SynthesisFrontiers in oncology2025
Visceral fat area as a prognostic biomarker in gastric cancer: a systematic review and meta-analysis of survival outcomes.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative contributions of visceral adiposity and muscle-related parameters to postoperative complications after gastrectomy: a domain-based analysis.BMC cancer · 2026Article
- Visceral adiposity rather than BMI predicts overall survival after curative gastrectomy for gastric cancer: a retrospective cohort study with age-stratified analyses.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Visceral fat area (VFA) has been suggested as an alternative to body mass index (BMI) for evaluating the effects of obesity and fat distribution. Although VFA has shown potential as a predictor of perioperative complications and surgical duration, its prognostic value in gastric cancer patients remains contentious. This meta-analysis aimed to elucidate the prognostic significance of VFA in this patient population. Methods: We searched the PubMed, Cochrane Library, CNKI, and EMBASE databases, including literature published up to July 31, 2024, to investigate the prognostic implications of VFA in postoperative and non-surgical gastric cancer patients. Outcome measures encompassed overall survival (OS), relapse-free survival (RFS), disease free survival (DFS). Results: A total of 6,054 eligible patients were selected from 12 studies. The results indicated a significant association between elevated VFA and improved OS and DFS/RFS (OS: HR 0.76, 95% CI 0.65-0.90, p = 0.001; DFS: HR 0.84, 95% CI 0.75-0.95, p = 0.004). Subgroup analyses were conducted to assess the robustness of these findings. Conclusions: This meta-analysis demonstrated that among patients with gastric cancer who underwent surgery or other treatments, elevated VFA was significantly associated with improved OS and DFS/RFS. Consequently, VFA may serve as a useful prognostic indicator for assessing the prognosis of gastric cancer patients following treatment. However, further prospective studies are necessary to validate these findings and confirm the reliability of VFA as a prognostic marker. Systematic review registration: https://inplasy.com/, identifier INPLASY202490078.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.